



## ***New Biotechnology* publication validates Crescendo Biologics' platform as it moves towards the clinic**

**Cambridge, UK, 25 October 2019** – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted, T cell enhancing therapeutics, announces a publication in the scientific journal, *New Biotechnology*, which provides in-depth validation of the Company's proprietary human V<sub>H</sub> transgenic platform<sup>1</sup>.

The full paper on Crescendo's platform can be accessed online [HERE](#).

The paper's authors describe Crescendo's platform which is based on a triple knock-out (TKO) background. The platform responds robustly to immunisation by producing large numbers of diverse, high-affinity, fully human antibody V<sub>H</sub> domains (Humabodies), while the production of regular antibodies is silenced.

Humabodies are small, *in vivo* matured building blocks that can be easily assembled into multifunctional molecules, which can be configured for optimal engagement with multiple therapeutic targets in ways which can be challenging for regular antibody formats. Humabodies penetrate rapidly into and accumulate efficiently in target tissues. Their systemic exposure can be modulated using Crescendo's serum albumin-binding domains, optimising the therapeutic index to allow prolonged systemic exposure or rapid clearance from circulation.

### **Theodora Harold, CEO of Crescendo Biologics said:**

"Crescendo's transgenic Humabody® platform underpins our innovative portfolio of targeted T cell enhancing immuno-oncology programmes, so the publication in *New Biotechnology* is important validation for us. Our lead proprietary programme, CB307, is a novel CD137-PSMA bispecific which selectively activates tumour-specific T cells exclusively within the tumour microenvironment. Using our proprietary platform, CB307 has been designed to achieve a more durable anti-cancer effect whilst avoiding systemic toxicity. The programme is on track to enter the clinic in 2020."

**-Ends-**

### **References**

<sup>1</sup> Authors: Teng, Y., Young, J., Edwards, B., Hayes, P., Thompson, L., Johnston, C., Edwards, C., Sanders, Y., Writer, M., Pinto, D., Zhang, Y., Roode, M., Chovanec, P., Matheson, L., Corcoran, A., Fernandez, A., Montoliu, L., Rossi, B., Tosato, V., Gjuracic, K., Nikitin, D., Bruschi, C., McGuinness, B., Sandal, T. and Romanos, M. (2019). *New Biotechnology*, 55, pp.65-76.



For more information, please contact:

<b>Crescendo Biologics</b> <b>Theodora Harold, CEO</b>	<b>Tel: 44 (0)1223 497140</b> <a href="mailto:info@crescendobiologics.com">info@crescendobiologics.com</a>
<b>Instinctif Partners</b> <b>Melanie Toyne-Sewell / Dr Christelle Kerouedan</b> <b>/ Phil Marriage</b>	<b>Tel: 44 (0)20 7457 2020</b> <a href="mailto:crescendo@instinctif.com">crescendo@instinctif.com</a>

## Notes to Editors

### About Crescendo Biologics

Crescendo Biologics is a T cell enhancing company. Crescendo develops potent, truly differentiated Humabody® therapeutics with a focus on innovative, targeted T cell approaches in oncology.

Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel CD137-PSMA bispecific for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity and is on track to enter the clinic in 2020.

The Company's ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® V<sub>H</sub>). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional IgG approaches. Humabody®-based formats can also be applied across a range of non-cancer indications.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.

For more information, please visit the website: [www.crescendobiologics.com](http://www.crescendobiologics.com)